Compare NGNE & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | NX |
|---|---|---|
| Founded | 2003 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 834.5M |
| IPO Year | 2014 | 2008 |
| Metric | NGNE | NX |
|---|---|---|
| Price | $23.57 | $18.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $77.88 | $26.00 |
| AVG Volume (30 Days) | 354.4K | ★ 379.4K |
| Earning Date | 11-12-2026 | 09-03-2026 |
| Dividend Yield | N/A | ★ 1.66% |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | ★ $1,837,641,000.00 |
| Revenue This Year | N/A | $1.98 |
| Revenue Next Year | N/A | $0.51 |
| P/E Ratio | ★ N/A | $33.89 |
| Revenue Growth | N/A | ★ 43.81 |
| 52 Week Low | $15.93 | $11.04 |
| 52 Week High | $43.66 | $23.33 |
| Indicator | NGNE | NX |
|---|---|---|
| Relative Strength Index (RSI) | 33.88 | 45.11 |
| Support Level | $16.88 | $18.30 |
| Resistance Level | $29.16 | $19.62 |
| Average True Range (ATR) | 1.99 | 0.76 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 29.31 | 40.70 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.